Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

Published Erratum

. 2015 Oct 16;4(10):e001991.

doi: 10.1161/JAHA.115.001991.

No authors listed

Published Erratum

No authors listed. J Am Heart Assoc. 2015.

. 2015 Oct 16;4(10):e001991.

doi: 10.1161/JAHA.115.001991.

No abstract available

Erratum for

Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.
Gaziano JM, Cincotta AH, Vinik A, Blonde L, Bohannon N, Scranton R. Gaziano JM, et al. J Am Heart Assoc. 2012 Oct;1(5):e002279. doi: 10.1161/JAHA.112.002279. Epub 2012 Oct 25. J Am Heart Assoc. 2012. PMID: 23316290 Free PMC article. Clinical Trial.

Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus.
Siamashvili M, Davis S. Siamashvili M, et al. Expert Opin Pharmacother. 2021 Feb;22(2):241-247. doi: 10.1080/14656566.2020.1825683. Epub 2020 Oct 8. Expert Opin Pharmacother. 2021. PMID: 33030357 Review.
Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary.
Raskin P, Cincotta AH. Raskin P, et al. Expert Rev Endocrinol Metab. 2016 Mar;11(2):113-148. doi: 10.1586/17446651.2016.1131119. Expert Rev Endocrinol Metab. 2016. PMID: 30058874
Bromocriptine in type 2 diabetes mellitus.
Shivaprasad C, Kalra S. Shivaprasad C, et al. Indian J Endocrinol Metab. 2011 Jul;15(Suppl 1):S17-24. doi: 10.4103/2230-8210.83058. Indian J Endocrinol Metab. 2011. PMID: 21847449 Free PMC article.
Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR.
Bell DS. Bell DS. Postgrad Med. 2012 Sep;124(5):121-35. doi: 10.3810/pgm.2012.09.2598. Postgrad Med. 2012. PMID: 23095432 Review.
Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.
Scranton R, Cincotta A. Scranton R, et al. Expert Opin Pharmacother. 2010 Feb;11(2):269-79. doi: 10.1517/14656560903501544. Expert Opin Pharmacother. 2010. PMID: 20030567